ATE321856T1 - Humane rezeptortyrosinkinase - Google Patents

Humane rezeptortyrosinkinase

Info

Publication number
ATE321856T1
ATE321856T1 AT99955501T AT99955501T ATE321856T1 AT E321856 T1 ATE321856 T1 AT E321856T1 AT 99955501 T AT99955501 T AT 99955501T AT 99955501 T AT99955501 T AT 99955501T AT E321856 T1 ATE321856 T1 AT E321856T1
Authority
AT
Austria
Prior art keywords
tyrosine kinase
human receptor
receptor tyrosine
well
kinase
Prior art date
Application number
AT99955501T
Other languages
English (en)
Inventor
Namit Ghildyal
Govindaswamy Panchamoorthy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of ATE321856T1 publication Critical patent/ATE321856T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Processing Of Solid Wastes (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AT99955501T 1998-06-11 1999-06-08 Humane rezeptortyrosinkinase ATE321856T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8895898P 1998-06-11 1998-06-11

Publications (1)

Publication Number Publication Date
ATE321856T1 true ATE321856T1 (de) 2006-04-15

Family

ID=22214506

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99955501T ATE321856T1 (de) 1998-06-11 1999-06-08 Humane rezeptortyrosinkinase

Country Status (8)

Country Link
US (2) US6969596B2 (de)
EP (1) EP1084245B1 (de)
JP (1) JP2002517241A (de)
AT (1) ATE321856T1 (de)
AU (1) AU4278299A (de)
DE (1) DE69930662T2 (de)
ES (1) ES2262347T3 (de)
WO (1) WO1999064589A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
AU5173400A (en) * 1999-05-28 2000-12-18 Sugen, Inc. Protein kinases
US6734162B2 (en) 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
AR028424A1 (es) * 2000-05-10 2003-05-07 Bayer Corp Metodo para regular la angiogenesis utilizando proteina ryk
WO2002087618A1 (en) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Preventive/therapeutic method for cancer
US20040138160A1 (en) * 2001-04-27 2004-07-15 Kenichiro Naito Preventive/therapeutic method for cancer
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
US20050239088A1 (en) * 2003-05-16 2005-10-27 Shepard H M Intron fusion proteins, and methods of identifying and using same
US7741070B2 (en) * 2003-12-24 2010-06-22 Massachusetts Institute Of Technology Gene targets for enhanced carotenoid production
US20090222931A1 (en) * 2004-05-13 2009-09-03 Tsinghua University Novel identified oncogene with kinase-domain (nok)
EP1745073A2 (de) * 2004-05-14 2007-01-24 Receptor Biologix, Inc. Isoformen eines zelloberflächenrezeptors und verfahren zu deren identifizierung und anwendung
WO2006042002A2 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
GB0807018D0 (en) * 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
WO2011036297A2 (de) * 2009-09-27 2011-03-31 Ruhr-Universität-Bochum Verfahren zur therapie und diagnose von morbus alzheimer
WO2024146628A1 (en) * 2023-01-06 2024-07-11 Nanjing Legend Biotech Co., Ltd. Engineered immune cells and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684136A (en) 1992-05-18 1997-11-04 Genentech, Inc. Chimeric hepatocyte growth factor (HGF) ligand variants
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
WO1995030331A1 (en) * 1994-05-05 1995-11-16 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US5763198A (en) 1994-07-22 1998-06-09 Sugen, Inc. Screening assays for compounds
US5763470A (en) 1995-06-07 1998-06-09 Sugen Inc. Benzopyran compounds and methods for their use
AU2066797A (en) * 1996-03-21 1997-10-10 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors

Also Published As

Publication number Publication date
US20050208566A1 (en) 2005-09-22
DE69930662D1 (de) 2006-05-18
ES2262347T3 (es) 2006-11-16
EP1084245B1 (de) 2006-03-29
US20030078222A1 (en) 2003-04-24
US6969596B2 (en) 2005-11-29
WO1999064589A1 (en) 1999-12-16
JP2002517241A (ja) 2002-06-18
DE69930662T2 (de) 2006-12-28
AU4278299A (en) 1999-12-30
EP1084245A1 (de) 2001-03-21

Similar Documents

Publication Publication Date Title
DE69930662D1 (de) Humane rezeptortyrosinkinase
CY1106723T1 (el) Ν-τελικα μονοπεγυλιωμενα συζευγματα ανθρωπινης αυξητικης ορμονης, διεργασιες για την παρασκευη τους και μεθοδοι χρησης αυτων
DK0813545T3 (da) Nukleotid- og proteinsekvenser af hvirveldyrs-Serrate-gener og fremgangsmåde baseret derpå
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
NO20065528L (no) Forbindelser som fremmer vevsvekst.
EA200200755A1 (ru) Опосредованная рецептором nogo блокада роста аксонов
DK0861261T3 (da) Nukleotid- og proteinsekvenser af hvirveldyrs-Delta-gener og fremgangsmåder baseret derpå
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
CY1116164T1 (el) Προδρομη 4-σουλφαταση ν-ακετυλογαλακτο σαμινης, μεθοδοι θεραπευτικης αγωγης που χρησιμοποιουν το εν λογω ενζυμο και μεθοδοι για παραγωγη και καθαρισμο του εν λογω ενζυμου
DE69028101D1 (de) Melaninkonzentrierende hormone und dns die diese expremieren
AP0202540A0 (en) Inhibitors of interleukin -1B converting enyme.
ATE337339T1 (de) Therapeutische verwendung von smr1 protein und seinen aktiven derivaten
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
GB0322645D0 (en) Use of antisecretory factor peptides
WO2000060062A3 (en) Human signal transduction serine/threonine protein kinase
ATE285794T1 (de) Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien
ATE309200T1 (de) Antikonvulsive und zns-aktive bis-fluoralkylamide
ATE494903T1 (de) Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden
EA038283B1 (ru) Способ лечения или предупреждения остеоартрита
ATE300554T1 (de) Bindegewebe-wachstumsfaktor 3.
DE69829995D1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
Wirtz et al. In vivo and in vitro noncovalent association of excised alpha 1 (I) amino-terminal propeptides with mutant pN alpha 2 (I) collagen chains in native mutant collagen in a case of Ehlers-Danlos syndrome, type VII.
CN1477117A (zh) 新型人磷脂酰乙醇胺结合蛋白，其编码序列及用途

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties